Non‑conventional Fotemustine Schedule as Second‑line Treatment in Recurrent Malignant Gliomas: Survival Across Disease and Treatment Subgroup Analysis and Review of the Literature
Molecular and Clinical Oncology - United Kingdom
doi 10.3892/mco.2018.1746
Full Text
Open PDFAbstract
Available in full text
Date
October 16, 2018
Authors
Publisher
Spandidos Publications